CASI Pharmaceuticals, Inc. announced that James E. Goldschmidt, Ph.D. to lead its business development team. Dr. Goldschmidt is responsible for developing new partnerships and brings to the Company more than 25 years of biotechnology and pharmaceutical experience, including most recently at Macrophage Therapeutics, and prior thereto at ImmuneXcite, TetraLogic Pharmaceuticals, Johnson & Johnson, Wyeth Pharmaceuticals, and SmithKline Beecham.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 USD | +1.03% | -5.19% | -62.99% |
Mar. 28 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 05 | Top Midday Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.99% | 34.42M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- CASI Stock
- News CASI Pharmaceuticals, Inc.
- CASI Pharmaceuticals Appoints James E. Goldschmidt as Vice President of Business Development